U.S. markets closed

Avenue Therapeutics, Inc. (ATXI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2959+0.0080 (+2.78%)
At close: 04:00PM EDT
0.2960 +0.00 (+0.03%)
After hours: 07:30PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.2879
Bid0.2826 x 1000
Ask0.2990 x 1200
Day's Range0.2700 - 0.2969
52 Week Range0.2000 - 1.8500
Avg. Volume268,909
Market Cap6.55M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateAug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ATXI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Avenue Therapeutics, Inc.
    CARA: What does Argus have to say about CARA?CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Abeona Therapeutics Announces Strategy Update and 2021 Financial Results

    EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans Company to focus R&D resources primarily on VIITAL™ data readout while actively pursuing potential commercialization partner for EB-101; maintain focus on preclinical eye gene therapy programs Pursue strategic partner to take over development activities for ABO-102 for MPS IIIA

  • Benzinga

    FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol

    Avenue Therapeutics Inc (NASDAQ: ATXI) announced the outcome of the FDA meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. The Advisory Committee had to vote on "has the Applicant submitted adequate information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic in an inpatient setting?" The result

  • GlobeNewswire

    Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

    NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. In the final part of the public meeting, the Advisory Committee voted yes or no on